Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug—dupilumab—that showed rapid and sustained improvements in patients in a pivotal Phase 3 clinical trial, researchers report in the New England Journal of Medicine. This monoclonal antibody is the first biologic shown to improve clinical outcomes in COPD. The data supporting the use of dupilumab in COPD will be reviewed by the United States Food and Drug Administration in June.
Medical Xpress – latest medical and health news stories
